Telix Pharmaceuticals Limited (TLX-AU): Radiant in cancer therapy

Free to access research and investor meetings in a post-MiFID2 world

Telix Pharmaceuticals Limited (TLX-AU): Radiant in cancer therapy
Recommendation: OUTPERFORM
Target Price: AUD$ 2.50
Current Price: AUD$ 0.625 (COB on 23^rd April 2018)

KEY TAKEAWAY

With radio-pharmaceutical valuations riding high, Telix has assembled a unique product portfolio that exploits the natural synergy between radio-imaging and radio-therapy; meeting urgent unmet needs in kidney, prostate and brain cancer. Addressing substantial markets, the commercial strategy balances risk against reward. Well characterised and heavily de-risked imaging products and a niche orphan therapy sold direct by Telix lead the charge; a much-anticipated renal cancer diagnostic entering pivotal phase III. The higher value clinical stage therapeutic programmes for big pharma partnering following close behind. De-risked and diversified, the stock looks substantially undervalued on the basis of our DCF, as well as the multi-billion-dollar acquisitions and several-fold market capitalisations of key peers. We initiate with an OUTPERFORM recommendation and a target price of AUD 2.5 / share.

Urgent need for better diagnostics - There is an urgent need for better diagnosis in prostate and kidney cancers. Too frequently mis-diagnosis results in inappropriate or unneeded intervention. The increasing complexity of the therapeutic options can only be navigated with the right imaging tools for disease and treatment monitoring.

De-risked diagnostics move to market - Telix has focussed on well characterised and much anticipated diagnostic tests. The forerunner of Telix's renal diagnostic now moving into a confirmatory pivotal Phase III previously received 16-0 from an FDA advisory committee. The agent upon which the Telix prostate diagnostic is based is widely considered the most effective of the current imaging options. Telix's convenient 'shake and shoot' solution now makes its wide-scale use practicable. Marketed directly by Telix, these products should see rapid adoption.

Huge promise in cancer therapies - Advances in radio-isotopes and dosing regimes that unleash the synergy between radiotherapy and immunity are yielding exciting results. Proof of concept trials involving Telix's radiopharmaceuticals indicate efficacy in renal, prostate and brain cancers; with improved overall survival in advanced prostate and one patient with brain cancer potentially disease-free. Telix imaging products should streamline trial design and facilitate broader clinical use.

Substantial upside - Sold direct the Telix imaging portfolio represents a significantly, but relatively de-risked opportunity with the higher valued therapeutics offering significant upside. Our DCF analysis indicates that the current market valuation is justified on the basis of the imaging programmes alone and ascribes little or no value to therapeutics; despite the quality of data in all three programmes. Our risk adjusted analysis indicates a fair value of AUD 2.5 / share with upside of AUD 4.5 / share should the products achieve their full therapeutic potential.

Kind regards,

Dr. Chris Redhead | Analyst
goetzpartners Healthcare Research Team | Research Team

goetzpartners securities Limited

The Stanley Building, 7 Pancras Square, London, N1C 4AG, England, UK.

T +44 (0) 203 859 7725 | healthcareresearch@goetzpartners.com / chris.redhead@goetzpartners.com

www.goetzpartnerssecurities.com

Registered in England No. 04684144.

Managing Directors: Dr Stephan Goetz, Martin Brunninger and Ulrich Kinzel.

GPSL publishes and distributes "Investment" Research and "Corporate Sponsored" Research. Our Corporate Sponsored Research and investor meetings (e.g. NDRs, 1 to 1 meetings) are free to access and attend and is not classified as an inducement in a post-MiFID2 world. GPSL does not offer any execution or market making services. This is a marketing communication as defined by the Financial Conduct Authority ("FCA"). The information herein is considered to be an acceptable minor non-monetary benefit as defined under FCA COBS 2.3A19(5).

To be added, or to change your subscriptions or be removed / unsubscribed entirely from our CRM, please e-mail: ResearchProduction@goetzpartners.com

About GPSL: goetzpartners securities Limited is a member of the goetzpartners group and a leading true pan European investment bank and research firm. We bring together a wide range of expertise, insights and innovations to advance the interests of our clients around the world. The fast changing environment brings challenges for businesses and investors. Research innovation, digital transformation and disruptive business ideas reshuffle the corporate world in a yet unexperienced pace. Our sector knowledge and our global footprint bring together deep understanding of the industry, corporate intelligence and a wide network of top decision makers.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

This e-mail (including any attachments) from goetzpartners securities Limited ("GPSL") is confidential and may contain information which is proprietary, privileged or otherwise legally protected against unauthorised use or disclosure. If you receive this e-mail in error or are not the intended recipient of this e-mail, please delete and destroy all copies in your possession, notify the sender that you have received this e-mail, and note that any review or dissemination of, or the taking of any action in reliance on this e-mail is expressly prohibited. GPSL shall not be liable for the improper or incomplete transmission of the information contained in this e-mail nor for any delay in its receipt or damage to your system. GPSL does not guarantee that the integrity of this e-mail has been maintained nor that this e-mail is free of viruses, interceptions or interference and makes no warranties in relation to these matters. This is not an offer or a solicitation to buy or sell securities or investment products, or an official confirmation. GPSL record electronic and phone communications in accordance with FCA and MiFID2 regulations, they will be monitored for regulatory and training purposes. GPSL is authorised and regulated by the Financial Conduct Authority of the United Kingdom (Firm Reference Number: 225563).

GPSL Equity Research publications are available on the following aggregators and via news distribution circuits (For Institutional Use Only): AlphaSense, Bloomberg (GOET), Capital IQ, EQS, FACTSET,
RNS Reach and Thomson Reuters.

If you cannot click on the above hyperlink please copy the below link and paste it into your browser for the full pdf version of the equity research report:

https://gp.bluematrix.com/sellside/EmailDocViewer?encrypt=d13d8770-00d1-4642-ad5d-0b39a9236425&mime=pdf&co=gp&id=paul.dunne@goetzpartners.com&source=libraryView